SPL Insider Trading

Insider Ownership Percentage: 7.38%
Insider Buying (Last 12 Months): A$66,499.92
Insider Selling (Last 12 Months): A$0.00

Starpharma Insider Trading History Chart

This chart shows the insider buying and selling history at Starpharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Starpharma Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for SPL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Starpharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/15/2024Robert ThomasInsiderBuy100,000A$0.13A$13,000.00
4/12/2024Russell BasserInsiderBuy71,428A$0.14A$9,999.92
4/10/2024Robert ThomasInsiderBuy250,000A$0.17A$43,500.00
12/8/2023Jacinth (Jackie) FairleyInsiderIssued667,441A$0.14A$90,104.54
10/6/2023Jacinth (Jackie) FairleyInsiderExpiry514,918A$0.14A$69,513.93
12/5/2022Jacinth (Jackie) FairleyInsiderIssued1,139,651A$0.55A$621,109.80
10/31/2022Robert ThomasInsiderBuy50,000A$0.52A$26,000.00
9/12/2022Jacinth (Jackie) FairleyInsiderBuy30,000A$0.57A$17,190.00
12/3/2021Jacinth (Jackie) FairleyInsiderIssued493,360A$1.21A$594,498.80
10/1/2021Jacinth (Jackie) FairleyInsiderCancelled224,712A$1.30A$292,125.60
8/30/2021Jacinth (Jackie) FairleyInsiderBuy50,000A$1.16A$58,000.00
8/27/2021Robert ThomasInsiderBuy25,000A$1.16A$29,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Starpharma (ASX:SPL)

38.59% of Starpharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Starpharma logo
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
Read More on Starpharma

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

351,391 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

9.30%

Beta

0.76

Who are the company insiders with the largest holdings of Starpharma?

Starpharma's top insider investors include:
  1. Jacinth (Jackie) Fairley (Insider)
  2. Robert Thomas (Insider)
  3. Russell Basser (Insider)
Learn More about top insider investors at Starpharma.